Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis
- PMID: 2260855
- DOI: 10.1002/ana.410280514
Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis
Abstract
The level of soluble interleukin-2 receptor (sIL-2R) was quantitated with enzyme-linked immunosorbent assay in serum and cerebrospinal fluid obtained from 24 patients with multiple sclerosis and 10 patients with other neurological disorders in whom immunological mechanisms are unlikely to participate. The sIL-2R level in the serum and cerebrospinal fluid of patients with multiple sclerosis in relapse was significantly higher compared with patients with multiple sclerosis in remission and with controls. The sIL-2R level, especially in the cerebrospinal fluid, showed higher sensitivity and specificity than other clinical parameters including the cerebrospinal fluid IgG ratio, peripheral lymphocyte CD4/CD8 ratio, cerebrospinal fluid myelin basic protein and oligoclonal bands. Our data suggest that measurement of the sIL-2R level may be useful in evaluating disease activity in patients with multiple sclerosis.
Similar articles
-
Soluble interleukin-2 receptor and soluble CD8 molecules in cerebrospinal fluid and serum of patients with multiple sclerosis.Eur Cytokine Netw. 1992 Sep-Oct;3(5):495-8. Eur Cytokine Netw. 1992. PMID: 1477299
-
Soluble interleukin-2 receptors in cerebrospinal fluid from individuals with various neurological disorders.Ann Neurol. 1990 Aug;28(2):168-73. doi: 10.1002/ana.410280209. Ann Neurol. 1990. PMID: 2221845
-
Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma.Br J Dermatol. 1996 May;134(5):843-7. Br J Dermatol. 1996. PMID: 8736323
-
Detection of myelin basic protein in cerebrospinal fluid.Expert Rev Mol Diagn. 2002 Nov;2(6):627-33. doi: 10.1586/14737159.2.6.627. Expert Rev Mol Diagn. 2002. PMID: 12465458
-
Multiple sclerosis: IL-2 and sIL-2R levels in cerebrospinal fluid and serum. Review of literature and critical analysis of ELISA pitfalls.Mult Scler. 1998 Feb;4(1):7-11. doi: 10.1177/135245859800400103. Mult Scler. 1998. PMID: 9532585 Review.
Cited by
-
The IL-2 - IL-2 receptor pathway: Key to understanding multiple sclerosis.J Transl Autoimmun. 2021 Sep 21;4:100123. doi: 10.1016/j.jtauto.2021.100123. eCollection 2021. J Transl Autoimmun. 2021. PMID: 35005590 Free PMC article. Review.
-
Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.J Neurol. 1995 Jan;242(2):53-8. doi: 10.1007/BF00887815. J Neurol. 1995. PMID: 7707089
-
In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis.J Neurol. 1993 Jan;240(1):46-50. doi: 10.1007/BF00838446. J Neurol. 1993. PMID: 8423463
-
Soluble interleukin 2 receptor is risk for sarcopenia in Men with high fracture risk.J Orthop Translat. 2022 Nov 16;38:213-219. doi: 10.1016/j.jot.2022.10.017. eCollection 2023 Jan. J Orthop Translat. 2022. PMID: 36439626 Free PMC article.
-
Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.Mult Scler. 2014 Feb;20(2):156-64. doi: 10.1177/1352458513494488. Epub 2013 Jul 11. Mult Scler. 2014. PMID: 23846354 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials